• Policy
• Dual punishment for CSO rebates passes NA committee
• by Lee, Jeong-Hwan Mar 24, 2023 05:48am

• Company
• Discussion of reimbursement for Vyndamax is running in place
• by Eo, Yun-Ho Mar 24, 2023 05:48am

• Company
• 5th time the charm for Tagrisso’s reimbursement extension?
• by Jung, Sae-Im Mar 24, 2023 05:48am

• Policy
• Rinvoq also succeeded in expanding youth atopy benefits
• by Lee, Tak-Sun Mar 24, 2023 05:48am

• Opinion
• [Reporter's view]Vaccine self-sufficiency rate to 80%
• by Kim, Jin-Gu Mar 23, 2023 04:45am

• Policy
• Pharma industry makes a request to MOTIE and MOEF
• by Nho, Byung Chul Mar 23, 2023 04:45am

• Policy
• Legislation requiring submission of botulinum strains
• by Lee, Jeong-Hwan Mar 23, 2023 04:45am

• Company
• Neurofibromatosis Tx Koselugo makes progress for reimb
• by Eo, Yun-Ho Mar 23, 2023 04:45am

• Company
• Promoting the extension of the term of drug patents
• by Kim, Jin-Gu Mar 23, 2023 04:45am

• InterView
• The rebate effect is not just employee deviation
• by Kim JiEun Mar 22, 2023 05:47am